U.S. stock market update: Sarepta Therapeutics down 7.05%

U.S. Stock Market Midday Update Sarepta Therapeutics, down 7.05%, with increased trading volume. Based on recent key news: On August 21, Sarepta announced the exchange of approximately $700 million of its 1.25% convertible bonds maturing in 2027 for $602 million of new bonds maturing in 2030, along with stock and cash, leading to a 6.5% drop in stock price. On August 20, Sarepta faced a securities class action lawsuit due to safety issues with its gene therapy ELEVIDYS, further undermining investor confidence and causing a decline in stock price. On August 19, Sarepta faced multiple lawsuits due to safety issues and regulatory setbacks, resulting in a continued decline in stock price. Top Stocks by Industry Trading Volume Zhilin Group, up 159.90%, with a trading volume of $819 million. Based on recent key news: On August 21, Zhilin Group announced an all-stock merger with DiamiR Biosciences, with DiamiR becoming a wholly-owned subsidiary of Zhilin Group. The merged company is expected to continue listing on NASDAQ, leading to a 148.08% increase in stock price. On August 21, DiamiR Biosciences received approval for its APOE gene typing test from the New York State Department of Health, a significant development for the company’s innovative blood diagnostic tests, further boosting stock price. On August 21, Zhilin Group received formal notification from NASDAQ confirming that the company has regained compliance with NASDAQ's minimum bid requirements, enhancing market confidence and driving stock price up. Protagenic Therapeutics, up 115.37%. Based on recent important news: On August 21, Protagenic Therapeutics issued a press release announcing the company's strong financial condition, attracting investor attention and significantly boosting stock price. On August 19, the market reacted sensitively to increased competition in the obesity treatment sector, affecting the stock price of Protagenic Therapeutics. On August 19, retail investors continued to buy shares, driving up the stock price of Protagenic Therapeutics. AbbVie, up 1.10%, with a trading volume of $415 million. Based on recent key news: On August 21, AbbVie announced positive topline results from its second Phase 3 UP-AA study, showing significant efficacy of upadacitinib in treating patients with severe alopecia areata, pushing stock price up by 1.10%. On August 20, a large purchase of AbbVie shares was made on behalf of Ritchie Torres, which was positively received by the market, leading to an increase in stock price On August 19, AbbVie completed the acquisition of Capstan Therapeutics, enhancing its competitiveness in the biotechnology sector, and the stock price rose. Stocks ranked among the top in industry market capitalization Amgen rose by 0.38%, with a market capitalization of $160.2 billion. Based on recent important news: On August 20, market analysts believe Amgen is not the best investment choice currently, leading to a lack of investor confidence and stock price fluctuations. On August 19, Hansoh Pharmaceutical's share placement was discounted by 6.49%, affecting the overall sentiment in the biopharmaceutical industry. On August 18, Zhongwei Co., Ltd. released its semi-annual report, showing a revenue growth of 6.16%, boosting market confidence